Biblio Discovery — Demo Discovery Service

11 results for "Catherine Schmidt-Mutter"

Showing 1–11 · 1.32 seconds · RSS

  1. Journal Article

    Dopamine precursor depletion affects performance and confidence judgements when events are timed from an explicit, but not an implicit onset

    Ljubica Jovanovic; Morgane Chassignolle; Catherine Schmidt-Mutter et al.

    Scientific Reports, Vol. 13 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Dopamine affects processing of temporal information, but most previous work has tested its role in prospective tasks, where participants know in advance when the event to be timed starts. However, we are often exposed to events whose onset we do not know in advance. We can evaluate their…

  2. Journal Article Full text

    Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy

    Nicolas Collongues; Brigitte Samama; Catherine Schmidt-Mutter et al.

    PLOS ONE, Vol. 13 No. 1 · 2018 · English · PLOS Scopus

    Background: Skin biopsy is the most relevant tool to diagnose small-fiber neuropathy. A well-documented normal dataset for intraepidermal nerve fiber in the distal leg is required to improve its diagnostic value. Methods: Three hundred healthy subjects were enrolled in the study, after clinical and…

    Also available at: DOAJ

  3. Journal Article Full text

    Increased expression of blood muscarinic receptors in patients with reflex syncope

    Maxime Beutelstetter; Angelo Livolsi; Hugues Greney et al.

    PLOS ONE, Vol. 14 No. 7 · 2019 · English · PLOS Scopus

    Aims: Pathophysiology of reflex syncope is not fully understood but a vagal overactivity might be involved in this syncope. Previously, overexpression of muscarinic M2 receptors and acetylcholinesterase was found in particular in the heart and in lymphocytes of rabbits with vagal overactivity as…

    Also available at: DOAJ

  4. Journal Article Full text

    Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

    Floriane Gallais; Pierre Gantner; Timothée Bruel et al.

    EBioMedicine · 2021 · English · OpenAlex Scopus

    BACKGROUND: Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting risk of reinfection and durability of vaccine protection. METHODS: This is a prospective, monocentric, longitudinal, cohort clinical study. Healthcare workers (HCW) from Strasbourg University Hospital were…

    Also available at: DOAJ

  5. Journal Article Full text

    Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

    Adeep Puri; Andrew J. Pollard; Catherine Schmidt-Mutter et al.

    Vaccines, Vol. 12 No. 2 · 2024 · English · DOAJ Scopus

    In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, or 3 clinical studies. The study was conducted at…

  6. Journal Article

    Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial

    Cécile Janssen; Marine Cachanado; Laetitia Ninove et al.

    EClinicalMedicine, Vol. 48 · 2022 · English · DOAJ Scopus

    Summary: Background: Although effective mRNA vaccines for SARS-CoV-2 infection have been deployed worldwide, their interchangeability could facilitate the scale-up of vaccination programs. The objective of the trial was to assess whether the immune response induced by a heterologous SARS-CoV-2 mRNA…

  7. Journal Article

    Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants

    Odile Launay; Rachna Gupta; Tifany Machabert et al.

    Communications Medicine, Vol. 5 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to…

  8. Journal Article

    Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

    Christine Durier; Laetitia Ninove; Maeva Lefebvre et al.

    Scientific Reports, Vol. 12 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Immune response induced by COVID-19 vaccine booster against delta and omicron variants was assessed in 65 adults (65–84 years old) early aftesr a first booster dose. An increase in SARS-CoV-2 neutralizing antibodies was shown in individuals not previously infected without evidence of an…